You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023498037
Dec 2023172014
Jan 20247906
Feb 2024192023
Mar 2024164023
Apr 2024134013
May 2024132016
Jun 20248605
Jul 2024122014
Aug 2024118010
Sep 20248807
Oct 2024258017
Nov 2024256012
Dec 2024320011
Jan 2025248021
Feb 2025104013
Mar 20250022
Apr 20250017
May 2025005
Jun 2025008
Total29710294